Combinatorial	O
CRISPR	O
/	O
Cas9	O
Approach	O
to	O
Elucidate	O
a	O
Far	O
-	O
Upstream	O
Enhancer	O
Complex	O
for	O
Tissue	O
-	O
Specific	O
Sox9	O
Expression	O
.	O


SRY	O
-	O
box	O
9	O
(	O
SOX9	O
)	O
is	O
a	O
master	O
transcription	O
factor	O
that	O
regulates	O
cartilage	O
development	O
.	O


SOX9	O
haploinsufficiency	O
resulting	O
from	O
breakpoints	O
in	O
a	O
~	O
1	O
-	O
Mb	O
region	O
upstream	O
of	O
SOX9	O
was	O
reported	O
in	O
acampomelic	O
campomelic	O
dysplasia	O
(	O
ACD	O
)	O
patients	O
,	O
suggesting	O
that	O
essential	O
enhancer	O
regions	O
of	O
SOX9	O
for	O
cartilage	O
development	O
are	O
located	O
in	O
this	O
long	O
non	O
-	O
coding	O
sequence	O
.	O


However	O
,	O
the	O
cis	O
-	O
acting	O
enhancer	O
region	O
regulating	O
cartilage	O
-	O
specific	O
SOX9	O
expression	O
remains	O
to	O
be	O
identified	O
.	O


To	O
identify	O
distant	O
cartilage	O
Sox9	O
enhancers	O
,	O
we	O
utilized	O
the	O
combination	O
of	O
multiple	O
CRISPR	O
/	O
Cas9	O
technologies	O
including	O
enrichment	O
of	O
the	O
promoter	O
-	O
enhancer	O
complex	O
followed	O
by	O
next	O
-	O
generation	O
sequencing	O
and	O
mass	O
spectrometry	O
(	O
MS	O
)	O
,	O
SIN3A	O
-	O
dCas9	O
-	O
mediated	O
epigenetic	O
silencing	O
,	O
and	O
generation	O
of	O
enhancer	O
deletion	O
mice	O
.	O


As	O
a	O
result	O
,	O
we	O
could	O
identify	O
a	O
critical	O
far	O
-	O
upstream	O
cis	O
-	O
element	O
and	O
Stat3	O
as	O
a	O
trans	O
-	O
acting	O
factor	O
,	O
regulating	O
cartilage	O
-	O
specific	O
Sox9	O
expression	O
and	O
subsequent	O
skeletal	O
development	O
.	O


Our	O
strategy	O
could	O
facilitate	O
definitive	O
ACD	O
diagnosis	O
and	O
should	O
be	O
useful	O
to	O
reveal	O
the	O
detailed	O
chromatin	O
conformation	O
and	O
regulation	O
.	O
